Straight from the Desk
Syz the moment
Live feeds, charts, breaking stories, all day long.
- All
- equities
- United States
- Macroeconomics
- Food for Thoughts
- markets
- Central banks
- Fixed Income
- bitcoin
- Asia
- europe
- investing
- geopolitics
- technical analysis
- gold
- Commodities
- Crypto
- AI
- Technology
- nvidia
- ETF
- earnings
- Forex
- china
- Real Estate
- oil
- banking
- Volatility
- energy
- magnificent-7
- apple
- Alternatives
- emerging-markets
- switzerland
- tesla
- United Kingdom
- Middle East
- assetmanagement
- amazon
- russia
- ethereum
- microsoft
- ESG
- meta
- Industrial-production
- bankruptcy
- Healthcare
- Turkey
- Global Markets Outlook
- africa
- Market Outlook
- brics
- performance
Investors learn the most by studying other investors' mistakes
Source: Brian Feroldi
Higher real bond yields create a challenge for global equities valuations
Source: Bloomberg
"The real money in investment will be made not out of buying and selling but of owning and holding securities" - Charlie Munger
Source: Investment Books (Dhaval)
Eli Lilly stock hit a new record high yesterday as the company continues to record a surge in sales for its buzzy diabetes drug Mounjaro
Sales of Mounjaro, which has also gained popularity for weight loss, came in at $979.7 million for the second quarter, up from $16 million a year earlier when it was introduced (2Q results were publichsed 2 weeks ago). That helped the drug company post higher-than-expected sales for the second quarter. Novo Nordisk is also surfing on the strong demand for a similar weight loss blockbuster
Over 60% of outstanding US mortgages have an interest rate below 4%. Current average 30y mortgage rate is north of 7.5%...
This is the 1 factor driving the limited housing supply as many of these homeowners can't afford to move... Source: Charlie Bilello, National Mortgage Database
Bitcoin's correlation to the sp500 has shown signs of breaking down Lower correlation boosts BTC's diversification potential
Source: Game of trades
Investing with intelligence
Our latest research, commentary and market outlooks

